亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

P-02.04 Developing T cell bispecific antibodies with reduced-affinity anti-CD3 binders for a potent, efficacious, and low-cytokine response

作者
Omar Abdelmotaleb,C Klein,Inja Waldhauer,Johannes Sam,Thomas Höfer,Martin Lechmann,Anne Freimoser–Grundschober,Miro Julian Eigenmann,Ali Bransi,Alex Odermatt,Peter Brünker,Sara Colombetti,Anina Schneider
出处
期刊:Journal for ImmunoTherapy of Cancer [BMJ]
卷期号:: A17.1-A17
标识
DOI:10.1136/jitc-2025-itoc11.28
摘要

Background T cell bispecifics (TCBs) were conventionally considered to require high affinities for both CD3 and tumor target binders to activate T cells and achieve efficient tumor cell killing. Based on this approach, TCBs have successfully achieved efficacy in treating patients with hematological and more recently solid tumors, but their mode-of-action has been associated with cytokine release which has been dose-limiting in some cases. Recent studies suggested that lowering CD3 binder affinity may result in effective tumor killing with reduced cytokine levels. However, the possible interdependence of CD3 affinity with additional parameters to achieve this outcome still remains untackled. This study aims to understand the impact of the CD3 and tumor-target binder affinity on differential T cell-dependent cytotoxicity and cytokine secretion. Therefore, a series of TCBs with different affinities for CD3, along with two target binders of differing affinities (high and low) targeting FOLR1 and CEACAM5, were developed in a 2:1 TCB format. This configuration allows for bivalent, preferential binding to the tumor antigen and monovalent binding to CD3, providing a distinct opportunity to enhance the activity of conventional TCBs. Materials and Methods In vitro, 2:1 TCBs were tested using human peripheral blood mononuclear cells (PBMCs) and human tumor cell lines to evaluate T cell-mediated cytotoxicity and cytokine release. In vivo, we investigated the impact our TCBs have on efficacy, cytokine release, and pharmacokinetic properties in stem cell-engrafted humanized mouse models. Results CD3 binders were categorized into high, intermediate, low, and very low affinity groups based on SPR analysis and functional assays. CD3intermed produced lower cytokine levels compared to CD3high while maintaining T cell mediated cytotoxicity regardless of the target. Additionally, CD3low exhibited a favorable profile in comparison to CD3high only when coupled with a high-affinity target binder, resulting in even lower cytokine levels than those induced by CD3intermed. By utilizing advanced humanized mouse models, we demonstrated the in vitro to in vivo translatability of our findings across targets using CD3 affinity-attenuated binders, as opposed to the typical use of PBMC-engraftment models in published studies. Lastly, we observed that CD3 affinity does not impact PK properties in vivo. Conclusions We confirmed that reducing CD3 affinity in our 2:1 TCB platform can maintain anti-tumor efficacy while lowering cytokine release. Most importantly, the selection of the target binder affinity and the appropriate preclinical models are crucial for determining the optimal CD3 affinity threshold. O. Abdelmotaleb: A. Employment (full or part-time); Significant; Roche. E. Ownership Interest (stock, stock options, patent or other intellectual property); Significant; Roche. C. Klein: None. I. Waldhauer: None. J. Sam: None. T. Hofer: None. M. Lechmann: None. A. Freimoser-Grundschober: None. M. Eigenmann: None. A. Bransi: None. A. Odermatt: None. P. Brünker: None. S. Colombetti: None. A. Schneider: None.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
复杂的士萧完成签到 ,获得积分10
4秒前
5秒前
8秒前
9秒前
卉卉完成签到,获得积分10
12秒前
林xq完成签到 ,获得积分10
13秒前
愉快的泥猴桃完成签到 ,获得积分10
15秒前
黄黄胖胖的龙完成签到,获得积分10
15秒前
标致访旋完成签到,获得积分10
17秒前
21秒前
22秒前
22秒前
NinjiaQiu完成签到 ,获得积分10
24秒前
24秒前
李李发布了新的文献求助10
26秒前
27秒前
清脆世界完成签到 ,获得积分10
28秒前
青柳雅春发布了新的文献求助10
28秒前
动听问旋完成签到,获得积分10
32秒前
醉熏的小小完成签到 ,获得积分10
34秒前
34秒前
38秒前
落后裙子完成签到,获得积分10
39秒前
Clover04的应助被海绵宝宝采纳,获得10
42秒前
乐迪发布了新的文献求助10
44秒前
Ren的应助被落后裙子采纳,获得100
44秒前
44秒前
青柳雅春完成签到,获得积分10
47秒前
得财完成签到,获得积分20
48秒前
Maestro_S的应助被科研通管家采纳,获得10
50秒前
Maestro_S的应助被科研通管家采纳,获得10
51秒前
51秒前
CAOHOU的应助被科研通管家采纳,获得10
51秒前
51秒前
无花果的应助被科研通管家采纳,获得10
51秒前
风吹麦浪的应助被科研通管家采纳,获得10
51秒前
大模型的应助被或大或小采纳,获得10
53秒前
54秒前
cyanpomelo完成签到,获得积分10
55秒前
56秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184991
求助须知:如何正确求助?哪些是违规求助? 9573924
关于积分的说明 21833782
捐赠科研通 7782458
什么是DOI,文献DOI怎么找? 3434459
关于科研通互助平台的介绍 2558672
邀请新用户注册赠送积分活动 2481161